MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to determine lipid changing effects of MK0524A when compared to niacin extended release (NIASPAN) and placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• Patients must be between the ages of 18 and 70 years

• Female patients must be pre-menopausal women that have been surgically sterilized, not pregnant and/or not planning to become pregnant

Exclusion Criteria:

• Patient has a history of peptic ulcer or gout

• Patient is sensitive to niacin or products containing niacin

• Patient drinks more than 2 alcoholic drinks per day

• Patient has certain heart disease, cancer, or is HIV positive